Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
125 studies found for:    MPDL3280A
Show Display Options
Rank Status Study
1 Recruiting Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
Condition: Bladder Cancer
Intervention: Drug: MPDL3280A
2 Active, not recruiting MPDL3280A-treatment-IST-UMCG
Conditions: Bladder Cancer;   Non Small Cell Lung Cancer;   Breast Cancer
Intervention: Drug: MPDL3280A
3 Recruiting MPDL3280A-imaging-IST-UMCG
Conditions: Breast Cancer;   Bladder Cancer;   Non Small Cell Lung Cancer
Intervention: Other: 89Zr-MPDL-3280A-PET scans
4 Recruiting Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MPDL3280A;   Drug: Nab-paclitaxel
5 Active, not recruiting A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Radiation: Hypofractionated Radiotherapy
6 Recruiting Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MPDL3280A;   Drug: Carboplatin;   Drug: Nab-paclitaxel
7 Active, not recruiting A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Rociletinib;   Drug: MPDL3280A
8 Recruiting Study of MPDL3280A in Bladder Cancer
Condition: Carcinoma, Transitional Cell
Interventions: Drug: MPDL3280A Dose Level 1;   Drug: MPDL3280A Dose Level 2;   Drug: MPDL3280A Dose Level 3
9 Active, not recruiting A Phase 1 Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Intervention: Drug: Atezolizumab
10 Recruiting Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Condition: Small Cell Lung Cancer ( SCLC )
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Biological: MPDL3280A
11 Recruiting A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Conditions: Non-small Cell Lung Cancer;   Urothelial Carcinoma
Interventions: Drug: atezolizumab;   Drug: epacadostat
12 Recruiting MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A;   Radiation: Stereotactic Body Radiation Therapy
13 Recruiting Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CDX-1401;   Drug: MPDL3280A
14 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Condition: Solid Tumor
Intervention: Drug: Atezolizumab
15 Recruiting A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Atezolizumab
16 Recruiting A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
17 Recruiting A Study to Assess Pharmacokinetics and Safety of Atezolizumab Administered Intravenously to Chinese Participants With Locally Advanced or Metastatic Solid Tumors (IMYO29233)
Condition: Neoplasms
Intervention: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
18 Recruiting An Open-Label Study of Atezolizumab in Advanced Solid Tumors
Condition: Solid Tumor
Intervention: Drug: Atezolizumab [TECENTRIQ]
19 Active, not recruiting
Has Results
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
20 Not yet recruiting Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Advanced Non-small Cell Lung Cancer
Intervention: Drug: Atezolizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.